NCT00065156CompletedPhase 2
A Multicenter, Single-arm, Open-label Study of the Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion-dependent Subjects With Myelodysplastic Syndromes Associated With a Del(5q) Cytogenetic Abnormality.
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Celgene
- Enrollment
- 148
- Locations
- 29
- Primary Endpoint
- Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence
Study Overview
Brief Summary
This study is a multicenter, single-arm, open-label study of oral lenalidomide monotherapy administered to red blood cell (RBC) transfusion-dependent subjects with low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del (5q31-33) cytogenetic abnormality. Screening procedures will take place within 28 days of the first day of lenalidomide treatment. Subjects will receive lenalidomide in 28-day cycles for up to 6 cycles, or until bone marrow disease progression or progression/relapse following erythroid hematologic improvement is documented. Study visits will occur every cycle (every 28 days) and laboratory monitoring to assess hematological parameters will occur every 14 days. Safety and efficacy assessments to be performed during the study are outlined in the Schedule of Study Assessments.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Must understand and voluntarily sign an informed consent form
- •Age 18 years or older at the time of signing the informed consent
- •Must be able to adhere to the study visit schedule and other protocol requirements.
- •Diagnosis of low or intermediate-1-risk International Prognostic Scoring System (IPSS) Myelodysplastic Syndromes (MDS) without an abnormality of chromosome 5 involving a deletion between bands q31 and q
- •Red blood cell (RBC) transfusion-dependent anemia defined as having received greater than or equal to 2 units of RBCs within 8 weeks of the first day of study drug treatment.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or
- •Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug.
- •Sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.
- •WCBP must agree to have pregnancy tests every 4 weeks while on study drug.
Exclusion Criteria
- •Pregnant or lactating females
- •Prior therapy with lenalidomide.
- •An abnormality of chromosome 5 involving a deletion between bands q31 and q
- •Lab Abnormality: Absolute neutrophil count (ANC) <500 cell/mm^3 (0.5*10^9/L)
- •Lab Abnormality: Platelet count <50,000/mm^3 (50*10^9/L)
- •Lab Abnormality: Serum creatinine >2.5 mg/dL (221 mmol/L)
- •Lab Abnormality: Serum total bilirubin >2.0 mg/dL (34 mmol/L)
- •Prior greater than or equal to grade 3 National Cancer Institute (NCI) Common Toxicity Criteria (CTC) allergic reaction/hypersensitivity to thalidomide.
- •Clinically significant anemia due to factors such as iron, B12 or folate deficiencies, autoimmune or hereditary hemolysis or gastrointestinal bleeding
- •If a marrow aspirate is not evaluable for storage iron, transferrin saturation must be > 20% and serum ferritin not less than 50 ng/mL
- •Use of hematopoietic growth factors within 7 days of the first day of study drug treatment.
- •Prior greater than or equal to grade 3 NCI CTC rash or any desquamation (blistering) while taking thalidomide.
- •Chronic use (>2 weeks) of greater than physiologic doses of a corticosteroid agent (dose equivalent to >10 mg/day of prednisone) within 28 days of the first day of study drug treatment.
- •Use of experimental or standard drugs (i.e. chemotherapeutic, immunosuppressive, and cytoprotective agents) for the treatment of MDS within 28 days of the first day of study drug treatment.
- •Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for greater than or equal to 3 years.
- •Use of any other experimental therapy within 28 days of the first day of study drug treatment.
Arms & Interventions
Lenalidomide
Experimental
Intervention: lenalidomide (Drug)
Outcomes
Primary Outcomes
Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence
Time Frame: Up to 2 years
Number of participants who achieved RBC-transfusion independence, which was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (eg, Days 1 to 56, Days 2 to 57, Days 3 to 58, etc), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin.
Secondary Outcomes
- Kaplan Meier Estimate for Duration of Transfusion Independence Response(up to 2 years)
- Change in Hemoglobin Concentration From Baseline to Maximum Value During Response Period for Responders(Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years))
- Participants With Adverse Experiences(Up to 2 Years)
- Participants Who Relapsed or Maintained Their Transfusion Independence After Achieving Transfusion Independence During the Study(up to 2 years)
- Participants With a >= 50% Decrease From Baseline in Red Blood Cell (RBC) Transfusion Requirements Over Any Consecutive 56 Days During Study(Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years))
- Time to Transfusion Independence(up to 2 years)
- Participant Counts of Cytogenetic Response(up to 2 years)
- Participant Counts of Platelet Response(up to 2 years)
- Participant Counts of Absolute Neutrophil Count (ANC) Response(up to 2 years)
- Participants With Complete or Partial Bone Marrow Improvement(up to 2 years)
- Participants With Bone Marrow Progression(up to 2 years)
Investigators
Study Sites (29)
Loading locations...
Similar Trials
Terminated
Phase 2
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.Prostate CancerNCT00179738Celgene Corporation40
Completed
Phase 4
Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)Hospital-Acquired PneumoniaNCT04774094Pfizer235
Terminated
Phase 1
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent AnemiaAcute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)LeukemiaAnemiaNCT01034592Jason Robert Gotlib2
Unknown
Phase 2
Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosisAlpha MannosidosisNCT01285700Zymenex A/S10
Active, not recruiting
Phase 2
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard TherapyColorectal CancerNCT05435313Fudan University39